Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with ...

Joe Walsh is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...

New research of a Martian meteorite suggests that water - an essential ingredient for life - arose in hot springs on Mars 4.4 billion years ago, at the same time as it did on Earth.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant depression. This marks a significant advancement in depression treatment ...

Spravato nasal spray is administered by the patient under ... In an effort to ensure the safe and appropriate use of Spravato, the medication is only available through a restricted program called ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...